HomeMarketZentalis Phar...

Zentalis Pharmaceuticals Inc. (NASDAQ:ZNTL) Stock initiated by Cowen

Cowen raised the price target for the Zentalis Pharmaceuticals Inc. (NASDAQ:ZNTL) stock to “an Outperform”. The rating was released on July 12, 2022, according to finviz. The research report from Jefferies has resumed the stock to Buy, with a price target set at $120. The stock was initiated by Stifel, who disclosed in a research note on September 30, 2021, to Buy and set the price objective to $84. In their research brief published September 29, 2021, Oppenheimer analysts initiated the Zentalis Pharmaceuticals Inc. stock to Outperform with a price target of $90.

The latest trade, Performances and Moving Averages give us the following Picture

The share price of Zentalis Pharmaceuticals Inc. (NASDAQ:ZNTL) raised 3.61% to close Thursday’s market session at $18.93, higher as compared to yesterday’s close. The stock price fluctuated between $17.79 and $19.47 throughout the trading session with the volume trading being 1069571 shares, which represented a significant variation when compared to the three months average volume of 534.34K shares. The firm’s stock price fluctuated 5.70% within the last five trades and -5.63% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -23.42% in the last 6 months and -5.30% was subtracted to its value over the previous 3 months. ZNTL stock is trading at a margin of 1.47%, -9.17% and -19.88% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


As of the close of trading, ZNTL deals in the Healthcare domain. The stock is trading -64.18 percent below its 52-week high and 21.74 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -55.1. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.

What Does Zentalis Pharmaceuticals Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?

The stock’s market cap achieved a total value of $1.25 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The firm managed a Price-to-Book ratio of 2.54, which equates the market value of a stock with its book value.

Is Insider Trading a Real Thing?

Gallagher Cam, the President at Zentalis Pharmaceuticals Inc. (ZNTL) has sold 8,501 shares of firm on Feb 14 at a price of $19.96 against the total amount of $0.17 million. In another inside trade, Bunker Kevin D., Chief Scientific Officer of Zentalis Pharmaceuticals Inc. (NASDAQ:ZNTL) sold 6,500 shares of the firm on Feb 14 for a total worth of $0.13 million at a price of $19.98. An inside trade which took place on Feb 14, Chief Financial Officer of Zentalis Pharmaceuticals Inc. Epperly Melissa B, sold 5,227 shares of firm against total price of $0.1 million at the cost of $19.98 per share.



Please enter your comment!
Please enter your name here

Recent Post